Positioning the New oral Anticoagulants for prevention of stroke in patients with non-valvular atrial fibrilation

Results * Results of comparative head-to head trials with NOAC show a trend towards dependence on the time that patients on the arm of VKA are in the therapeutic range. * The risks of bleeding for NOACs are greater in clinical practice than those observed in published clinical trials. * Treatment with NOAC (to start with or to switch on) should be carefully assessed in a case by case basis.